Ubs Asset Management Americas Inc Cerevel Therapeutics Holdings, Inc. Transaction History
Ubs Asset Management Americas Inc
- $277 Billion
- Q1 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 84,837 shares of CERE stock, worth $3.42 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
84,837
Previous 84,644
0.23%
Holding current value
$3.42 Million
Previous $3.59 Million
0.06%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CERE
# of Institutions
227Shares Held
150MCall Options Held
939KPut Options Held
961K-
Bain Capital Investors LLC Boston, MA65.7MShares$2.65 Billion61.94% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$435 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$304 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$301 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$220 Million0.01% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Market Cap $6.28B
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...